There are at least 5 potential mechanisms by which antimicrobial resistance can have adverse effects on human health. The first, called the "attributable fraction," relates to individuals who become infected only because they are taking an antimicrobial agent (for unrelated reasons) to which the pathogen is resistant: the antimicrobial agent, by suppressing their normal microbiota, renders them more vulnerable to infection. A second mechanism involves the linkage of virulence traits to resistance traits so that resistant organisms may be more virulent than susceptible organisms. A third mechanism is that treatment may be rendered ineffective by the choice of a drug to which the pathogens are resistant or may be complicated by the need to use an agent with less desirable attributes than would otherwise be the case. A fourth mechanism is the animal equivalent of the attributable fraction: resistant pathogens acquired by this mechanism in food animals may then be transmitted through the food chain to humans. Last, resistance traits can be acquired by the commensal flora of animals; from this reservoir, resistance traits could find their way through the food chain to commensals and pathogens of humans.
Simply showing that a growing proportion of pathogenic and commensal organisms isolated from food animals are resistant to antimicrobial agents is not enough to prove a human health threat. Rather, it must be demonstrated that, as a result of such antimicrobial resistance, infections are more numerous, or are more severe, or are less easily treated (i.e., outcomes are worse or treatments more costly) than would be the case otherwise. This article reviews the mechanisms by which antimicrobial resistance per se could cause adverse effects on human health (table 1) .
The relationship between antimicrobial drugs, antimicrobial resistance, and pathogenicity of microorganisms is exceedingly complicated, as is illustrated by the first mechanism. The commensal microbiota of the in-testine and other epithelial surfaces normally exerts a protective effect against colonization and infection by exogenous organisms. Treatment with antimicrobial agents often results in a reduction in various components of this microbiota. Therefore, subjects taking antimicrobial agents are, paradoxically, at increased risk of certain infections, both while taking the antimicrobial and for some days or weeks thereafter, until the microbiota is reconstituted. By means of statistical and epidemiologic analyses, a subset of patients can be identified who become infected only because their resistance to infection has been diminished by consumption of an antimicrobial. This subset of subjects has been called the "attributable fraction" (i.e., the fraction of infected subjects in whom this was the presumed mechanism), "etiologic fraction," or "excess cases." Although this phenomenon could theoretically apply also to subjects infected by antimicrobial-susceptible pathogens (provided they stopped taking the antimicrobial agent before exposure to the pathogen), virtually all evidence of the effect has emerged from studies of infection by antimicrobial-resistant strains (see Barza and Travers, in this supplement). This mechanism should not be confused with the phenomenon, demonstrated in humans and laboratory animals, by which the treatment of salmonella infections with certain antimicrobial agents appears to prolong shedding of the organism in the feces. That effect, the mechanism of which is uncertain, is seen primarily with drugs to which salmonella are susceptible and, therefore, is not relevant to the issue of antimicrobial resistance. A second potential mechanism by which antimicrobial resistance might increase the disease burden in humans is by genetic linkage of resistance traits and virulence factors, resulting in increased virulence of resistant strains. An increase in virulence would arise not directly from the antimicrobialresistance mechanism itself but from linkage of the resistance genes to other virulence genes. Cotransfer of the resistance trait and virulence genes could make drug-resistant pathogenic strains intrinsically more virulent than drug-susceptible strains. As a result, the infective dose could be reduced compared with that usually required, or, for a given infective dose, more people would become infected. Theoretically, it is also possible that resistant strains could be less virulent, but there is little direct evidence of this.
Infection by antimicrobial-resistant microorganisms might have worse outcomes due to ineffective initial treatment, the need to use less desirable treatment options, or both. The initial empiric treatment choice might be an antimicrobial agent to which the pathogen is resistant, leading to a delay in effective therapy. Effective agents might be more toxic, more expensive, or more difficult to administer than the traditional choice, which could have health or economic consequences. These phenomena are considered in Travers and Barza (in this supplement).
A fourth mechanism by which antimicrobial resistance can increase the human disease burden arises from an increase in the amount of pathogens (number of organisms, variety of species, or both) in animals. Exposure of food animals to antimicrobial agents might lead to increased colonization of the animals by drug-resistant pathogens. This is the same mechanism as the attributable fraction in humans (mechanism 1) but applying in this case to animals. This increase in the number of pathogens in food animals could lead to an increase in the burden of pathogens in the environment and in the food chain down to the human consumer. Furthermore, as in humans, most of these pathogens would presumably be resistant to antimicrobial agents. This phenomenon is considered by McEwen and Fedorka-Cray (in this supplement).
Finally, antimicrobial resistance arising in food animals could involve not just obvious pathogens (such as salmonella and campylobacter strains) but relatively nonpathogenic microbes such as Escherichia coli, enterococci, or Bacteroides species. These organisms could become reservoirs of antimicrobial resistance elements that could colonize humans via the food chain or environment (see Summers, in this supplement). The resistance elements could be transferred to ordinary pathogens or to other commensal bacteria that sometimes cause human disease, such as Klebsiella and Enterobacter species. Because these commensal species are not associated with food animals, the sources of these resistances could be difficult to discover. Vancomycin-resistant enterococci are an example of the transfer of resistant commensals from animals to humans (see Swartz, in this supplement). These are organisms of low pathogenicity except in patients with compromised defenses.
Only mechanisms 4 and 5 (described above) depend directly on the presence of the resistance traits in food animals; mechanisms 1 through 3 operate whatever the source is of the reDownloaded from https://academic.oup.com/cid/article-abstract/34/Supplement_3/S123/292856 by guest on 16 September 2019 sistance traits. However, pathogens such as Salmonella spp. and Campylobacter jejuni, which are the subject of this report, originate largely from the food chain. Therefore, in this context, even mechanisms 1 through 3 relate to the presence of resistance traits in bacteria from food animals. It is possible that subjects could ingest susceptible strains of these pathogens, with acquisition of drug resistance occurring in the human intestine, but there is little evidence that such events occur frequently.
By contrast, there is much evidence to indicate that the food chain already contains an abundance of antimicrobial-resistant pathogens. Therefore, for the purposes of this supplement, all 5 mechanisms can be considered as applying primarily to antimicrobial-resistant organisms arising from the farm. Taken together, these mechanisms provide an abundance of ways in which antimicrobial resistance originating in food animals can increase the impact of infectious diseases on humans.
